MORINAGA-MILK-INDUSTRY
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), the leading dairy product company in Japan, today announced the establishment of its new subsidiary, Morinaga Nutritional Foods (Asia Pacific) Pte. Ltd. located in Singapore. The new subsidiary company represents another step by Morinaga Milk to strengthen its ingredient sales operation in the fast-growing Asia Pacific market and to accelerate its globalization.
A vigorous demand for dairy products has been developing in Southeast Asian countries recently. Particularly in the emerging economies of Asia, the need for better infant nutrition is driving a strong demand for ingredients with higher quality.
Morinaga Milk began to expand globally over 40 years ago with the establishment in 1972 of its German subsidiary, Milei GmbH, and has been actively expanding exports of its functional and food ingredients, such as probiotics, lactoferrin and whey protein to leading infant formula manufacturers for long years.
Morinaga Nutritional Foods (Asia Pacific) handles Morinaga Milk’s safe and innovative functional and food ingredients - Bifidobacterium longum BB536 and other probiotics, whey proteins, lactose, lactoferrin and hydrolysates that are used in high-value nutritional products such as infant formulas by global and local customers. With the unique product values and innovative technology, Morinaga Nutritional Foods (Asia Pacific) is expected to establish a strong presence in the area.
“Singapore is now becoming a focal point for major global infant formula manufacturers and raw material suppliers as a location to strengthen their sales activities in Southeast Asia and Pacific Rim countries, thus we selected Singapore for the base of our ingredient sales activity in the region,” said Ko Shiino, General Manager of International Department in Morinaga Milk. “The location will enable the new subsidiary to better and faster serve its Asia Pacific customers and meet the growing market demand.”
“Our ingredients, such as probiotics, whey proteins and hydrolysates have been used in our own various food products with great success in Japan for many years, and have been also sold as raw materials overseas,” Shiino added. “We are well prepared to take this step to expand our ingredient business in the area and contribute to human health and nutrition throughout the world.”
About Morinaga Milk
Morinaga
Milk
is one of the largest dairy product companies in Japan,
employing over 3,000 people. Morinaga Milk achieved net sales of 5
billion USD at the end of fiscal 2015 year and is a market leader with
many top brands in yogurt, milk, infant formula, beverage, cheese,
butter, ice cream, pudding, dietary supplements and clinical foods.
Founded in 1917, Morinaga Milk exhibits excellence in the field of
technology and sells not only dairy products but also beneficial
functional ingredients manufactured in several manufacturing facilities
in Japan and Germany. Morinaga Milk also has joint ventures and
subsidiaries in China, the Netherlands, Indonesia and the U.S.A. for the
sales and production of dairy products, infant formulas, food
ingredients and long shelf-life tofu.
About Milei
Milei
manufactures and globally sells dairy ingredients derived from whey and
skim milk, such as whey protein, lactoferrin and lactose. Milei has been
expanding its production capacity since 2014, and will complete its
expansion by 2019.
If you would like more information about Morinaga Milk and Morinaga Nutritional Foods (Asia Pacific), please send an e-mail to: m-nozawa@morinagamilk.co.jp .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160119005759/en/
Contact:
Morinaga Milk Industry Co., Ltd.
Mai Nozawa, +81-3-3798-0152
m-nozawa@morinagamilk.co.jp
http://www.morinagamilk.co.jp/english/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom